Copyright
©The Author(s) 2025.
World J Exp Med. Sep 20, 2025; 15(3): 108984
Published online Sep 20, 2025. doi: 10.5493/wjem.v15.i3.108984
Published online Sep 20, 2025. doi: 10.5493/wjem.v15.i3.108984
Figure 2 Assessment of tumor-infiltrating programmed cell death protein 1 ligand 1-positive and SP142+ immune cells.
A: Programmed cell death protein 1 ligand 1-positive (PDCD1 LG1+) immune cell (IC) score < 10%; B: PDCD1 LG1+ IC score ≥ 10%; C: SP142 IC score < 1%; D: SP142+ IC score ≥ 1%. Staining with anti-PDCD1 LG1 antibodies (A and B), 200 ×; staining with anti-programmed death-ligand 1 antibodies (clone SP142)(C and D), 200 ×.
- Citation: Senchukova MA, Saidler NV, Zubareva EY, Prokofiev AB, Tagabilev DG. Concordance of programmed death-ligand 1 expression assessments determined via two immunohistochemical tests and the polymerase chain reaction method. World J Exp Med 2025; 15(3): 108984
- URL: https://www.wjgnet.com/2220-315X/full/v15/i3/108984.htm
- DOI: https://dx.doi.org/10.5493/wjem.v15.i3.108984